Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge.
BACKGROUND
There is debate whether patients with rapid-cycling bipolar disorder (BD) are predisposed to thyroid axis abnormalities and whether this may contribute to development of rapid mood shifts. Using lithium carbonate as a challenge to the hypothalamic-pituitary-thyroid (HPT) system, we determined whether patients with rapid-cycling BD are sensitive to the "antithyroid" properties of lithium.


METHODS
We studied the response to thyrotropin-releasing hormone (TRH) of HPT system hormones in 20 medication-free patients with rapid-cycling BD and compared these measurements with those of 20 healthy age- and gender-matched control subjects. The same measurements were repeated after both groups had received lithium carbonate for 4 weeks in sufficient doses to maintain blood levels between.7-1.2 mEq/L.


RESULTS
At baseline, the results of thyroid function tests, including the TRH challenge test, did not differ between patients and control subjects. After treatment with lithium, serum concentrations of thyroxine significantly decreased, whereas basal thyrotropin (TSH) and DeltaTSH(max) significantly increased in both patients and control subjects; however, patients had significantly higher DeltaTSH(max) after TRH stimulation. More patients than control subjects developed laboratory evidence consistent with grade III hypothyroidism after lithium treatment.


CONCLUSIONS
Rapid-cycling BD is associated with a latent hypofunction of the HPT system. This dysfunction becomes manifest with short-term lithium challenge.
Bipolar Disorders Program, Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA.
Laszlo
L
Gyulai
Michael
M
Bauer
Mark S
MS
Bauer
Felipe
F
García-España
Avital
A
Cnaan
Peter C
PC
Whybrow
D000328:Adult; D018692:Antimanic Agents; D013956:Antithyroid Agents; D001714:Bipolar Disorder / Q000503:physiopathology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D016651:Lithium Carbonate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013961:Thyroid Gland / Q000187:drug effects* / Q000503:physiopathology*; D013972:Thyrotropin / Q000097:blood / Q000187:drug effects; D013973:Thyrotropin-Releasing Hormone / Q000097:blood / Q000187:drug effects
D018692:Antimanic Agents; D013956:Antithyroid Agents; D016651:Lithium Carbonate; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin